Extremely premature infants who require mechanical ventilation face a difficult transition when clinicians attempt to remove the breathing tube. Extubation can be a major step toward recovery, yet some infants are unable to sustain independent breathing and must be reintubated. A pilot study published in the Journal of Perinatology is examining whether proteins circulating in the blood can help distinguish infants likely to succeed from those at risk of extubation failure.
The study, led by J.K. Fitzgerald, V. Ignjatovic, J.M. Morrison and colleagues, focuses on plasma proteomics, a technique that measures large numbers of proteins in the liquid portion of blood. Proteins act as signals, structural components, enzymes and regulators throughout the body. Because their concentrations can change in response to inflammation, tissue injury, infection, nutrition and organ development, they may provide a biochemical snapshot of an infant’s readiness to breathe without mechanical support.
For extremely premature neonates, the question is especially complex. Their lungs may still be developing, while the muscles and nervous-system circuits responsible for breathing remain immature. Mechanical ventilation can be lifesaving, but prolonged exposure may also contribute to lung injury and chronic respiratory problems. Clinicians therefore face a narrow therapeutic window: removing support too early can lead to respiratory collapse, while waiting too long can expose fragile lungs to additional complications.
The researchers characterized plasma protein signatures in relation to extubation outcomes, looking for patterns that differed between infants who remained successfully extubated and those who required renewed ventilatory assistance. In this context, a “signature” does not refer to a single diagnostic molecule. It describes a combination of proteins whose collective levels may reflect biological processes linked to respiratory stability, pulmonary inflammation, energy metabolism or systemic stress.
Proteomic analysis can reveal patterns that conventional clinical measurements may miss. Physicians routinely consider factors such as gestational age, birth weight, blood-gas values, oxygen requirements and ventilator settings when assessing extubation readiness. These measures describe how an infant is functioning at a particular moment, whereas plasma proteins may offer additional information about the underlying condition of the lungs and other organs. The goal is not to replace bedside judgment, but to add a molecular layer to an already complex decision.
The study is described as a pilot investigation, meaning its primary importance lies in exploring feasibility and identifying promising biological signals rather than establishing a definitive clinical test. Pilot studies generally involve limited numbers of participants and are designed to generate hypotheses for larger investigations. Any protein pattern associated with extubation outcome must therefore be tested in independent groups of infants before it can be used to guide treatment.
A reliable biomarker could eventually support more individualized respiratory care. Instead of applying the same extubation strategy broadly, clinicians might be able to combine proteomic information with clinical data to estimate an infant’s probability of success. Such an approach could help identify infants who need additional maturation or respiratory support, while avoiding unnecessary delays for those whose biology suggests they are prepared to breathe independently.
However, translating a proteomic signature into neonatal care presents substantial technical challenges. Blood samples from extremely premature infants must be collected in very small volumes, and protein measurements can be affected by sampling time, transfusions, medications, infection and the infant’s rapidly changing physiology. Researchers must also determine whether a signature reflects lung-specific biology or a broader response to illness. Reproducibility across hospitals, laboratories and different analytical platforms will be essential.
The findings add to a growing effort to use precision medicine in neonatology, where decisions often must be made with incomplete information and little margin for error. By connecting molecular patterns in plasma with the practical outcome of extubation, Fitzgerald and colleagues are testing whether proteomics can help answer one of the most consequential questions in neonatal intensive care. The work does not yet establish a clinical prediction tool, but it points toward a future in which a small blood sample could help clinicians make safer, more informed decisions for the most vulnerable newborns.
Subject of Research: Plasma proteomic signatures associated with extubation outcomes in extremely premature neonates
Article Title: Characterization of plasma proteomic signatures of extubation outcomes in extremely premature neonates: a pilot study
Article References: Fitzgerald, J.K., Ignjatovic, V., Morrison, J.M. et al. Characterization of plasma proteomic signatures of extubation outcomes in extremely premature neonates: a pilot study. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02859-8
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02859-8
Keywords: Extremely premature neonates; plasma proteomics; extubation outcomes; mechanical ventilation; neonatal intensive care; biomarkers; respiratory support
